BeiGene to Highlight Data from P-III (SEQUOIA) Study of Brukinsa in Combination with Venetoclax for CLL/SLL at EHA2024
Shots:
- BeiGene will highlight data from arm D of the P-III (SEQUOIA) study of Brukinsa + venetoclax among treatment-naïve high-risk CLL/SLL patients at EHA 2024
- The P-III (SEQUOIA) study for TN CLL/SLL has 3 cohorts, cohort 1 (n=479) for Brukinsa vs bendamustine + rituximab in patients without del(17p), cohort 2 (n=110) for Brukinsa alone in patients with del(17p) & cohort 3/arm D for Brukinsa + venetoclax in patients with del(17p) and/or TP53 mutation (n=66) & patients without del(17p) (n=48) were added later
- The study, in 65 evaluable patients from arm D, showed 100% ORR, 48% CR+CRi rate (CR=46%; CRi=2%) & undetectable MRD in 59% at a median follow-up of 31.6mos. with mPFS not attained and PFS of 95% (12mos.) & 94% (24mos.)
Ref: BeiGene | Image: BeiGene
Related News:- GenFleet Partners with BeiGene to Conduct P-Ib/II Trial of GFH009 and Brukinsa for the Treatment of Diffuse Large B Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
